Ocuphire Pharma, Inc. Overview
Pro stress-test →Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. The company acquired Opus Genetics in an all-stock transaction and was renamed Opus Genetics, Inc., trading under ticker symbol IRD effective October 24, 2024. The company now operates under the Opus Genetics name with a focus on gene therapy for inherited retinal diseases.
Strategic Profile
Pro stress-test →Ocuphire's historical pipeline included APX3330, an oral small-molecule inhibitor of Ref-1 being developed for diabetic retinopathy, and Phentolamine Ophthalmic Solution 0.75%, designed to reduce pupil size. The company's strategy evolved from small-molecule ophthalmic drugs toward adeno-associated virus-based gene therapies for inherited retinal diseases under the Opus Genetics name.
Competitive Landscape
Pro stress-test →Ocuphire/Opus Genetics competes in the ophthalmic biopharmaceutical and gene therapy space against larger players developing treatments for retinal diseases. Competitors include established ophthalmology companies and AAV-based gene therapy developers focusing on inherited retinal degenerations. The company operates at a significant scale disadvantage given its micro-cap status.
Industry Context
Ocuphire Pharma, Inc. operates in Gene therapy for inherited retinal diseases.
Key facts
Headquarters: Farmington Hills, MI · Market cap: $30.7M